Trial Profile
A retrospective study to evaluate functional and morphological outcomes of the treat-and-extend regimen (TER) with aflibercept in patients with typical choroidal neovascularization (CNV) and retinal angiomatous proliferation (RAP) secondary to exudative age-related macular degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 14 Feb 2017 New trial record